Table 2.

Adverse events occurring in >10% of the gefitinib therapy

Adverse events	First-line gefitinib				Second-line gefitinib
	21 mutation		19 deletion		21 mutation		19 deletion
	G1–2	G≥3	G1–2	G≥3	G1–2	G≥3	G1–2	G≥3
Non-hematological toxicity, n (%)
Rash	17 (77.2)	1 (4.5)	14 (73.6)	0	9 (81.8)	1 (9)	6 (75)	0
AST	14 (63.6)	4 (18.1)	10 (52.6)	2 (18.1)	7 (63.6)	2 (18.1)	5 (62.5)	2 (25)
ALT	13 (59.0)	3 (13.6)	11 (57.8)	3 (15.7)	6 (54.5)	4 (36.3)	6 (75)	2 (25)
Dry skin	12 (54.5)	0	8 (42.1)	0	6 (54.5)	0	3 (37.5)	0
Diarrhea	11 (50)	0	8 (42.1)	0	6 (54.5)	1 (9)	3 (37.5)	0
Fatigue	9 (40.9)	0	7 (36.8)	0	5 (45.5)	1 (9)	3 (37.5)	0
Paronychia	6 (27.2)	0	6 (31.5)	0	5 (45.5)	0	2 (25)	1 (12.5)
Stomatitis	5 (22.7)	0	4 (21)	0	3 (27.2)	0	3 (37.5)	0
Nausea	2 (9)	0	1 (5.2)	0	3 (27.2)	0	2 (25)	0
Constipation	2 (9)	0	1 (5.2)	0	1 (9)	0	2 (25)	0
Alopecia	2 (9)	0	1 (5.2)	0	1 (9)	0	1 (12.5)	0
Hematological toxicity, n (%)
Leucocytopenia	4 (18.1)	0	3 (15.7)	0	3 (27.2)	0	2 (25)	0
Thrombocytopenia	3 (13.6)	0	2 (10.5)	0	2 (18.1)	0	1 (12.5)	0
Neutropenia	1 (9)	0	0	0	2 (18.1)	0	1 (12.5)	0
Anemia	7 (31.8)	0	5 (5.2)	0	5 (45.4)	0	3 (37.5)	0

Abbreviations: G1–2, grade 1–2; G≥3, grade ≥3; AST, aspartate aminotransferase; ALT, alanine aminotransferase.